| Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 22143285 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Dipeptidyl peptidase-4 (DPP-4) inhibitors are some of the newest medications in our armamentarium for the management of type 2 diabetes mellitus. Through inhibition of the DPP-4 enzyme, these agents increase the amount of circulating incretin hormones, leading to an increase in insulin release and a suppression of glucagon secretion. Linagliptin is the third DPP-4 inhibitor approved by the Food and Drug Administration in the United States. It has been studied as monotherapy and as an adjunctive therapy to other oral agents in a dual or triple combination regimen. Linagliptin lowers glycosylated hemoglobin by about 0.4% when used as monotherapy and by about 0.5% to 1.1% when used in combination with other oral antihyperglycemic agents. Since linagliptin is mostly eliminated via the enterohepatic system (80%) and not to a significant extent through renal excretion, dosage adjustment is not necessary in patients with renal impairment. Linagliptin also has a favorable safety profile; nasopharyngitis is one of the more common observed side effects. Given its encouraging safety and efficacy profile, linagliptin is a good alternative to the other 2 agents in this class, especially for patients with renal impairment. This article provides a review of the pharmacologic and pharmacokinetic properties of linagliptin. The differences among the 3 available DPP-4 inhibitors will also be examined. |
| | |
Authors:
|
Rachael Aletti; Angela Cheng-Lai |
Related Documents
:
|
21792325 - Patient considerations and clinical utility of a fixed dose combination of saxagliptin/... 8249945 - The genetics of autoimmune diabetes. approaching a solution to the problem. 22225955 - Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome,... 21106865 - Incorporating incretin-based therapies into clinical practice: differences between gluc... 2859355 - Human blood-brain barrier insulin receptor. 3888565 - Group therapy in the treatment of diabetes. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Cardiology in review Volume: 20 ISSN: 1538-4683 ISO Abbreviation: Cardiol Rev Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2011-12-06 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9304686 Medline TA: Cardiol Rev Country: United States |
Other Details:
|
Languages: eng Pagination: 45-51 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy, Montefiore Medical Center/Jack D. Weiler Hospital of the Albert Einstein College of Medicine, Bronx, NY. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Vitamin d: a cardioprotective agent?
Next Document: High-internal-ionic liquid-phase emulsions.